Gerhard Niederfellner

2.8k total citations
36 papers, 1.9k citations indexed

About

Gerhard Niederfellner is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gerhard Niederfellner has authored 36 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Oncology and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gerhard Niederfellner's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Toxin Mechanisms and Immunotoxins (11 papers) and Glycosylation and Glycoproteins Research (7 papers). Gerhard Niederfellner is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Toxin Mechanisms and Immunotoxins (11 papers) and Glycosylation and Glycoproteins Research (7 papers). Gerhard Niederfellner collaborates with scholars based in Germany, Switzerland and United States. Gerhard Niederfellner's co-authors include A. Ullrich, Christian Klein, W. J. Issing, Bahija Jallal, Christian Wallasch, Ira Pastan, Karl‐Peter Hopfner, Birgit Bossenmaier, Guy Georges and Ekkehard Mössner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The EMBO Journal.

In The Last Decade

Gerhard Niederfellner

35 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerhard Niederfellner Germany	22	847	769	710	519	302	36	1.9k
Erwin R. Boghaert United States	26	1.0k 1.2×	1.2k 1.6×	513 0.7×	245 0.5×	321 1.1×	58	2.5k
Teemu T. Junttila Finland	24	2.4k 2.9×	1.6k 2.1×	1.6k 2.3×	441 0.8×	165 0.5×	32	3.7k
Amanda L. Christie United States	21	1.0k 1.2×	1.6k 2.1×	181 0.3×	275 0.5×	234 0.8×	34	2.4k
Ingo Ringshausen Germany	21	739 0.9×	1.0k 1.4×	113 0.2×	335 0.6×	387 1.3×	47	1.8k
Mary L. Bath Australia	22	1.2k 1.4×	2.0k 2.6×	153 0.2×	1.3k 2.5×	468 1.5×	30	3.5k
J H Pierce United States	17	1.0k 1.2×	1.5k 1.9×	156 0.2×	271 0.5×	103 0.3×	23	2.3k
Katrien Berns Netherlands	15	1.2k 1.5×	2.2k 2.9×	417 0.6×	172 0.3×	213 0.7×	19	3.0k
Toni M. Brand United States	19	807 1.0×	720 0.9×	213 0.3×	276 0.5×	105 0.3×	27	1.5k
Michelle Kuhne United States	14	788 0.9×	933 1.2×	213 0.3×	1.1k 2.0×	177 0.6×	35	2.2k
Mariana Nacht United States	17	441 0.5×	1.0k 1.3×	108 0.2×	268 0.5×	171 0.6×	27	1.5k

Countries citing papers authored by Gerhard Niederfellner

Since Specialization

Citations

This map shows the geographic impact of Gerhard Niederfellner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerhard Niederfellner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerhard Niederfellner more than expected).

Fields of papers citing papers by Gerhard Niederfellner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerhard Niederfellner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerhard Niederfellner. The network helps show where Gerhard Niederfellner may publish in the future.

Co-authorship network of co-authors of Gerhard Niederfellner

This figure shows the co-authorship network connecting the top 25 collaborators of Gerhard Niederfellner. A scholar is included among the top collaborators of Gerhard Niederfellner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerhard Niederfellner. Gerhard Niederfellner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hassan, Raffit, Christine Alewine, Idrees Mian, et al.. (2020). Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer. 126(22). 4936–4947. 40 indexed citations

O'Brien, James, Xiufen Liu, Tapan K. Bera, et al.. (2017). Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research. 5(8). 685–694. 39 indexed citations

Kollmorgen, Gwendlyn, Stefan Scheiblich, Fabian Birzele, et al.. (2017). A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer. Scientific Reports. 7(1). 18086–18086. 10 indexed citations

Liu, Xiu Fen, Laiman Xiang, Qi Zhou, et al.. (2016). Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Proceedings of the National Academy of Sciences. 113(38). 10666–10671. 60 indexed citations

Schanzer, Jürgen, Ute Jucknischke, Natalie J. Neubert, et al.. (2016). TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Engineering Design and Selection. 29(10). 467–475. 19 indexed citations

Bauss, Frieder, Martin Lechmann, Ben‐Fillippo Krippendorff, et al.. (2016). Characterization of a re‐engineered, mesothelin‐targetedPseudomonasexotoxin fusion protein for lung cancer therapy. Molecular Oncology. 10(8). 1317–1329. 48 indexed citations

Hollevoet, Kevin, et al.. (2015). Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Scientific Reports. 5(1). 10832–10832. 23 indexed citations

Liu, Xiufen, Tapan K. Bera, Masaki Terabe, et al.. (2015). Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

Sivasubramaniyan, K., Abhishek Harichandan, Karin Schilbach, et al.. (2015). Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology. 25(8). 902–917. 48 indexed citations

10.

Hollevoet, Kevin, et al.. (2014). In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer. Molecular Cancer Therapeutics. 13(8). 2040–2049. 93 indexed citations

11.

Alewine, Christine, Laiman Xiang, Takao Yamori, et al.. (2014). Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers. Molecular Cancer Therapeutics. 13(11). 2653–2661. 71 indexed citations

12.

Kobold, Sebastian, Julius Steffen, Michael Chaloupka, et al.. (2014). Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. JNCI Journal of the National Cancer Institute. 107(1). 364–364. 31 indexed citations

13.

Schiller, Christian, Thomas Friess, Christian A. Gerdes, et al.. (2013). RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation. Cancer Research. 73(16). 5183–5194. 85 indexed citations

14.

Kollmorgen, Gwendlyn, Gerhard Niederfellner, Alexander Lifke, et al.. (2013). Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Molecular Oncology. 7(6). 1142–1151. 26 indexed citations

15.

Klein, Christian, Alfred Lammens, Wolfgang Schäfer, et al.. (2013). Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 5(1). 22–33. 273 indexed citations

16.

Kollmorgen, Gwendlyn, Birgit Bossenmaier, Gerhard Niederfellner, Hans‐Ulrich Häring, & Reiner Lammers. (2012). Structural Requirements for Cub Domain Containing Protein 1 (CDCP1) and Src Dependent Cell Transformation. PLoS ONE. 7(12). e53050–e53050. 11 indexed citations

17.

Niederfellner, Gerhard, Alfred Lammens, Olaf Mundigl, et al.. (2011). Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 118(2). 358–367. 173 indexed citations

18.

Franke, Andreas G., Gerhard Niederfellner, Christian Klein, & Helmut Burtscher. (2011). Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines. PLoS ONE. 6(2). e16596–e16596. 21 indexed citations

19.

Kubota, Yoshiyuki, et al.. (1998). Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.. PubMed. 9(3). 247–56. 25 indexed citations

20.

Wallasch, Christian, et al.. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.. The EMBO Journal. 14(17). 4267–4275. 327 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact